AstraZeneca (AZN) Tops Q4 EPS by 8c

AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.21, $0.08 better than the analyst estimate of $1.13. Revenue for the quarter came in at $5.59 billion versus the consensus estimate of $5.57 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
• Merck (MRK) PT Raised to $155 at Scotiabank
• Magnificent 7 stocks lose $2.3 trillion in June